Morning Overview on MSN
A cell therapy for an aggressive childhood leukemia just won breakthrough status
Children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia now have a new reason to pay attention.
Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect ...
New preliminary clinical data presented at ISSCR 2026 evaluated an induced pluripotent stem cell (iPSC)-derived CAR T-cell ...
Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute report that ...
BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration ...
Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.
A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group ...
1d
Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)
Fate Therapeutics (FATE) pivots to autoimmune CAR T-cell therapies, with FT819 advancing toward a registrational lupus ...
CAR T-cell therapy is expected to expand quickly across autoimmune skin diseases following an anticipated regulatory approval that might come as soon as this year.
I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results